Skip to main content

FDA Approvals

Tafinlar plus Mekinist First Tumor-Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Page 8 of 53
Results 71 - 80 of 522